A comparison of buprenorphine taper outcomes between prescription opioid and heroin users

Journal of Addiction Medicine

Volumn 7, Issue 1, 2013, Pages 33-38

  Nielsen, Suzanne ^a,b   Hillhouse, Maureen ^a   Thomas, Christie ^a   Hasson, Albert ^a   Ling, Walter ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Buprenorphine taper; Induction; Opioids; Prescription opioid; Treatment

Indexed keywords

BUPRENORPHINE PLUS NALOXONE;

ADULT; ARTICLE; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HEROIN DEPENDENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OPEN STUDY; OPIATE ADDICTION; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY ANALYSIS; TREATMENT DURATION; TREATMENT PLANNING; URINALYSIS; WITHDRAWAL SYNDROME;

ADULT; BUPRENORPHINE; DEMOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEROIN; HUMANS; MALE; MIDDLE AGED; NARCOTIC ANTAGONISTS; NARCOTICS; OPIATE SUBSTITUTION TREATMENT; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME; UNITED STATES;

EID: 84877986631     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0b013e318277e92e     Document Type: Article

References (13)

1. Amass L, Kamien JB, Mikulich SK. Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. Drug Alcohol Depend 2000;58(1/2): 143-152.
2. Brands B, Blake J, Sproule B, et al. Prescription opioid abuse in patients presenting for methadone maintenance treatment. Drug Alcohol Depend 2004;73(2): 199-207.
3. Cacciola JS, Alterman AI, McLellan AT, et al. Initial evidence for the reliability and validity of a "Lite" version of the Addiction Severity Index. Drug Alcohol Depend 2007;87(2/3): 297-302.
4. Larance B, Ambekar A, Azim T, et al. The availability, diversion and injection of pharmaceutical opioids in South Asia. Drug Alcohol Rev 2011;30(3): 246-254.
5. Ling W, Hillhouse M, Domier C, et al. Buprenorphine tapering schedule and illicit opioid use. Addiction 2009;104(2): 256-265.
6. Manchikanti L, Fellows B, Ailinani H, et al. Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective. Pain Phys 2010;13(5): 401-435.
7. Maxwell JC. The prescription drug epidemic in the United States: a perfect storm. Drug Alcohol Rev 2011;30(3): 264-270.
8. McLellan AT, Kushner H, Metzger D, et al. The fifth edition of the Addiction Severity Index. J Subst Abuse Treat 1992;9(3): 199-213.
9. Moore BA, Fiellin DA, Barry DT, et al. Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients. J Gen Intern Med 2007;22(4): 527-530.
10. Sigmon SC, Dunn KE, Badger GJ, et al. Brief buprenorphine detoxification for the treatment of prescription opioid dependence: a pilot study. Addict Behav 2009;34(3): 304-311.
11. Weiss RD, Potter JS, Fiellin D, et al. A two-phase randomized controlled trial of adjunctive counseling during brief and extended buprenorphinenaloxone treatment for prescription opioid dependence. Arch Gen Psychiatry 2011;68(12): 1238-1246.
12. Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs 2003;35(2): 253-259.
13. Wu LT, Woody GE, Yang C, et al. Subtypes of nonmedical opioid users: results from the National Epidemiologic Survey on alcohol and related conditions. Drug Alcohol Depend 2010;112(1/2): 69-80.